Monteverde & Associates Probes Pacira BioSciences Merger Deal
A New York class action firm is investigating Pacira BioSciences over a potential merger, signaling shareholder concerns about the transaction's terms.
A prominent shareholder rights law firm has launched an investigation into Pacira BioSciences, Inc., the Nasdaq-listed pharmaceutical company trading under the ticker PCRX, according to a disclosure released in October 2026.
Monteverde & Associates PC, led by class action attorney Juan Monteverde, announced the probe, which is focused on a potential merger or acquisition involving Pacira BioSciences. The firm said it is examining whether the deal's terms adequately serve the interests of existing shareholders.
Read more Law Firm Probes Option Care Health Over Shareholder Rights →
The New York-based firm has positioned itself as a watchdog in merger-related litigation, having recovered millions of dollars for shareholders in prior cases. Monteverde & Associates was recognized as a Top 50 firm in the 2025 ISS Securities Class Action Services Report, lending institutional credibility to its oversight role in transactions of this nature.
Shareholder investigations of this type typically seek to determine whether a company's board fulfilled its fiduciary duties during the deal-making process — including whether a thorough market canvas was conducted and whether shareholders are receiving fair value. No lawsuit has been announced at this stage, and investigations do not always result in formal legal action.
Pacira BioSciences shareholders who wish to learn more about their legal rights in connection with the transaction are encouraged to contact the firm directly. Continue reading at All Financial Services & Investing.
